Cantor Fitzgerald maintained an Overweight rating on NewAmsterdam Pharma Company N.V. (NAMS) on February 19, 2026. The firm also reiterated a $49.00 price target in its note, as reported by market outlets. StreetInsider covered the update.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Explore Atect Corporation’s recent volume spike on the JPX. Discover key data, technical analysis, and insights on its performance in the Japanese con
SanDisk stock price focus: Kioxia JV extension to 2034 adds ¥170 billion, highlighting AI-fueled NAND flash demand and WDC stock moves. What Japan investors should watch today.
Explore the US government shutdown and Chuck Schumer’s stance. Analyze the economic impact and filibuster debate taking center stage.
Pride in Place expands to 40 areas in England with up to £800m and £180m for nine Welsh neighbourhoods. What this means for UK regeneration funding, high street investment, and investors.
SEPC.NS stock closes INR 9.02 on 06 Feb 2026 ahead of Feb 11 earnings; we highlight valuation, technicals and Meyka AI forecast
1738.HK stock down 12.59% pre-market Jan 2026; analysis of valuation, liquidity and Meyka AI forecast